BioNTech (BNTX) reported Q4 earnings Monday of 1.08 euros ($1.17) per diluted share, down from 1.88 euros a year earlier.
Comparable analyst estimates were not readily available.
Revenue for the quarter ended Dec. 31 was 1.19 billion euros, down from 1.48 billion euros a year earlier.
Analysts surveyed by FactSet expected 1.09 billion euros.
For 2025, the biotech firm expects revenue of 1.70 billion euros to 2.20 billion euros. Analysts polled by FactSet expect 2.54 billion euros.
Shares of the company were down more than 2.6% in recent premarket activity Monday.
Price: 106.00, Change: -2.78, Percent Change: -2.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。